Methyl 4-nitro-2-sulfamoylbenzoate
CAS: 2297-01-0
Rif. 3D-CAA29701
5mg | Fuori produzione | ||
25mg | Fuori produzione | ||
50mg | Fuori produzione | ||
100mg | Fuori produzione | ||
250mg | Fuori produzione | ||
500mg | Fuori produzione |
Informazioni sul prodotto
Methyl 4-nitro-2-sulfamoylbenzoate is a modified galactosylated drug that has been shown to inhibit the growth of cancer cells. Methyl 4-nitro-2-sulfamoylbenzoate binds to an enzyme called carbonic anhydrase, which is involved in the activation and deactivation of carbon dioxide. This drug inhibits the activity of this enzyme and prevents the conversion of carbon dioxide into bicarbonate ions, leading to a decrease in pH levels. Methyl 4-nitro-2-sulfamoylbenzoate also shows anticancer properties by inhibiting cyclin D1 and inducing apoptosis in cancer cells. The linker between the nitrobenzene group and methyl group is a triazole, which is synthesized using a chemical process that involves anhydride as a reagent.